Member Login


Adipokines as Drug Targets to Combat Adverse Effects of Excess Adipose Tissue

Welcome to the ADAPT Homepage

Programme under the call FP7-HEALTH-2007-A, SP-1 Cooperation, with contract no. HEALTH-F2-2008-201100. Coordinator: Juergen Eckel, German Diabetes Center

ADAPT is an EC-funded collaborative project of top European laboratories focusing on adipose tissue as a major endocrine organ. The major goal of this project is to identify novel or existing adipocytokines as drug targets that could be used to reverse obesity-associated inflammation and adverse reactions related to excess fat. The mustidisciplinary ADAPT consortium involves 11 partners and integrates basic and clinical science, bioinformatics, and in silico drug design. ADAPT is an inter-European collaborative network involving partners from Germany, Sweden, France and the Czech Republic.

If you are interested in obtaining further information about ADAPT, please contact the coordinator.

ADAPT, Diabetes, Adipokines, Obesity



The ADAPT project has been successfully completed on January 31, 2012 and the final report has been...


Final Scientific Meeting

The ADAPT project will be completed on January 31, 2012. To discuss the...


Final Meeting of COST Action BM0602

The final meeting of COST Action BM0602 "Adipose tissue:...


Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic...